Welcome to our dedicated page for Pulmatrix SEC filings (Ticker: PULM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Pulmatrix often means sifting through dense disclosures just to find a single update on cash runway or Phase 2 trial costs. Annual reports exceed 200 pages, and Form 4 insider trades can land minutes after market-moving data releases. Stock Titan eliminates that pain.
Our AI-powered summaries decode every Pulmatrix filing in real time, whether you need a Pulmatrix quarterly earnings report 10-Q filing or an 8-K that details a sudden licensing agreement. Stop scrolling: the platform flags R&D spend trends, milestone payments tied to the iSPERSE pipeline, and even rescues the footnotes that explain dilution risk.
Here鈥檚 what you鈥檒l find:
- Pulmatrix annual report 10-K simplified鈥擜I highlights trial timelines, cash burn, and key risk factors.
- Pulmatrix insider trading Form 4 transactions鈥攊nstant alerts showing executive sentiment, plus Pulmatrix Form 4 insider transactions real-time charts.
- Concise red-line comparisons of each Pulmatrix earnings report filing analysis so you can spot shifts in R&D priorities quarter over quarter.
- Clear breakdowns of the Pulmatrix proxy statement executive compensation package, formatted for quick scan.
- Pulmatrix 8-K material events explained鈥攆rom FDA feedback to partnership amendments鈥攄elivered with plain-language context.
Whether you鈥檙e understanding Pulmatrix SEC documents with AI for the first time, vetting a potential investment, or monitoring Pulmatrix executive stock transactions Form 4 ahead of catalyst dates, Stock Titan gives you the full picture鈥攏o medical dictionary required.
Pulmatrix (PULM) Q2-25 10-Q highlights: revenue fell to $0 from $1.6 m YoY as development work on PUR1900 wound down. Operating expenses dropped sharply to $1.5 m (-79%), driven by a 98% reduction in R&D to $14 k after the MannKind facility divestiture and staff cuts. Net loss narrowed to $1.5 m (-73%), or -$0.42/sh versus -$1.59/sh last year. Six-month net loss improved to $3.4 m from $5.0 m.
Cash & equivalents declined to $5.8 m (Dec-24: $9.5 m) after $3.7 m operating cash burn; management believes liquidity covers 鈮�12 months if the Cullgen merger is not completed. Stockholders鈥� equity fell to $5.6 m.
Cullgen merger: approved by Pulmatrix holders on 16-Jun-25; closing now targeted by 12-Oct-25 pending CSRC and Nasdaq approvals. Pre-merger Pulmatrix investors will receive a cash dividend for net cash above $2.5 m and retain only ~3.6% pro-forma ownership. Termination fees range from $0.42 m to $8.4 m. Failure to close could push Pulmatrix toward liquidation or require new funding.
Warrant liability was re-measured to $0, creating a $67 k gain; 918 k warrants remain outstanding, many expiring July-25. No ATM sales occurred in H1-25; share count steady at 3.65 m.
FAQ
What is the current stock price of Pulmatrix (PULM)?
What is the market cap of Pulmatrix (PULM)?
